TY - JOUR
T1 - Can every patient be mobilized?
AU - Dipersio, John F.
PY - 2010/12
Y1 - 2010/12
N2 - There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2 × 106 CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5 × 106 CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.
AB - There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2 × 106 CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5 × 106 CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.
KW - Allogeneic
KW - Autologous
KW - G-CSF
KW - GM-CSF
KW - Plerixafor
KW - Stem cell mobilization
UR - http://www.scopus.com/inward/record.url?scp=78649969472&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2010.09.011
DO - 10.1016/j.beha.2010.09.011
M3 - Review article
C2 - 21130416
AN - SCOPUS:78649969472
SN - 1521-6926
VL - 23
SP - 519
EP - 523
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 4
ER -